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The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. These NCCN Guidelines Insights summarize the NCCN Palliative Care Panel's discussions and guideline updates from 2013 and 2014, which include modifications/additions to palliative care screening and assessment protocols, new considerations for discussing the benefits and risks of anticancer therapy, and approaches to advance care planning. Recent updates focus on enhanced patient-centered care and seek to promote earlier integration of palliative care and advance care planning in oncology. Healthy lifestyle habits have been associated with improved health outcomes and quality of life and, for some cancers, a reduced risk of recurrence and death. The NCCN Guidelines for Survivorship therefore recommend that cancer survivors be encouraged to achieve and maintain a healthy lifestyle, including attention to weight management, physical activity, and dietary habits. This section of the NCCN Guidelines focuses on recommendations regarding nutrition, weight management, and supplement use in survivors.
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines
®
Head and Neck Cancers, Version 2.2014
This selection from the NCCN Guidelines for Head and Neck Cancers focuses on glottic laryngeal cancer. The lymphatic drainage of the glottis is sparse, and early-stage primaries rarely spread to regional nodes. Because hoarseness is an early symptom, most glottic laryngeal cancer is early stage at diagnosis. Updates to these guidelines for 2014 include revisions to "Principles of Radiation Therapy" for each site and "Principles of Surgery" and the addition of a new section on "Principles of Dental Evaluation and Management." Neel K. Gupta, MD, and Charalambos Andreadis, MD, MSCE This case report discusses a 75-year-old man with CLL complicated by massive splenomegaly, high-risk cytogenetics, and intolerance to first-line therapy recommended by the NCCN Guidelines. This report presents a brief summary of the treatment course and a discussion of the special challenges associated with treating this patient population. Emerging novel and targeted therapies are reviewed in the broader context of evolving standards of care and the NCCN Guidelines.
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Driven by reports of unmet clinical needs and lack of survival improvement, programs for adolescents and young adults (AYAs) with cancer have become increasingly common across the United States during the past 10 years, and organizations have published guidelines for AYA cancer care and for the development of clinical AYA programs. This article reviews these publications, describes the growth and development of 2 nationally recognized AYA centers, and offers practical suggestions to assist developing AYA programs. In an era of personalized medicine, an increased effort is being made to identify patients likely to benefit from targeted therapy. Restricting the use of anti-epidermal growth factor receptor-targeted agents in metastatic colorectal cancer to only patients with KRAS exon 2 wildtype tumors has become well-established. However, lack of KRAS exon 2 mutations does not necessarily predict response, and a significant proportion of patients with KRAS wild-type tumors do not benefit from therapy with cetuximab or panitumumab. This article focuses primarily on emerging data on non-exon 2 KRAS mutations and additional RAS and BRAF mutations and how this information may impact clinical decision-making.
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Optimizing Stem Cell Mobilization: Lessons Learned
Pamela S. Becker, MD, PhD
Granulocyte colony-stimulating factor is the pivotal component of mobilization regimens and the growth factor most often used for peripheral blood progenitor cell collections. When used alone or after chemotherapy, products with adequate yields of CD34 + cells are obtained after leukapheresis, resulting in optimal blood count recovery after transplant. However, for patients who have had extensive prior treatment with chemotherapy and/or radiation, or treatment with specific agents, the yields may be limited. This article discusses the modern methods that allow a high success rate for procurement of adequate stem cell products. In 2010, NCCN initiated the Opportunities for Improvement (OFI) project. Each participating NCCN Member Institution was provided data on guideline concordance and information on time to treatment from the NCCN outcomes database. A project team at each center reviewed these findings and established a program "charter" that outlined a specific plan to address quality issues within their breast cancer treatment system. This supplement to JNCCN includes the final reports from each of the NCCN centers participating in the project. The reports illustrate the range of opportunities for quality improvement in large multidisciplinary practices.
Metastatic Colorectal Cancer
Vol 11; Suppl 4, 2013 www.jnccn.org/content/11/suppl_4
The past decade has enriched our understanding of colorectal cancer biology and added complexity to the therapeutic armamentarium for patient with advanced disease. In this special supplement to JNCCN, multiple articles integrate a spectrum of treatment approaches, strategies, and challenges, reflecting comprehensive care for patients with metastatic colorectal cancer. Articles include a case report on management of the patient with synchronous metastatic rectal cancer; a discussion of KRAS and multigene assays, including their current and potential uses in colorectal cancer; a summary of the array of treatment opportunities for metastatic colorectal cancer patients, and a discussion of treatment sequencing in advanced unresectable disease. Finally, the early introduction of palliative care for patients with advanced disease is discussed. Most of the articles offer individual CE.
NCCN Task Force Report: Bone Health in Cancer Care
Vol 11; Suppl 3, 2013 www.jnccn.org/content/11/suppl_3
This report is the result of a multidisciplinary task force on bone health in cancer care convened by NCCN to discuss the progress made in assessing bone health; cancer therapy and bone loss; therapeutic strategies for maintaining bone health in patients with cancer; role of antiresorptive agents in preventing recurrences; pathophysiology of bone metastases and its complications; imaging and treatment of bone metastases; and safety and toxicity considerations while using antiresorptive agents. This NCCN Task Rorce report focuses on bone health and bone metastases in patients with breast and prostate cancer.
Data Needs in Oncology: "Making Sense of The Big Data Soup"
Vol 11; Suppl 2, 2013 www.jnccn.org/content/11/suppl_2
Rising health care costs and continued concerns about safety, efficacy, and quality have resulted in the demand for more data and evidence by payors, regulators, providers, and patients alike. In June 2012, NCCN assembled a work group composed of thought leaders from NCCN Member Institutions and other organizations to identify and examine the challenges of data generation, collection, and application for clinical, regulatory, and coverage decision-making. The NCCN Data Needs Work Group identified 4 main areas for consideration: data sources, patient-derived data, payor-collected data, and regulatory policy toward data generation and use.
Early Initiation of Palliative Care Interventions in Patients With Cancer, With an Emphasis on Management of Breakthrough Pain
Vol 11; Suppl 1, 2013 www.jnccn.org/content/11/suppl_1 Optimal cancer care requires the integration of palliative care into practice. A group of international experts met to review the current status of concurrent palliative and oncology care in different countries and to address questions related to why this integration does not occur on a more regular and effective basis. This supplement is a product of these discussions, which focused on key issues: development of a standard definition of palliative care and its component parts; models for care delivery; standardization of tools for patient assessment; educational programs designed to meet the needs of health care professionals; and the importance of developing best practices in symptom management using breakthrough pain management as an example.
